Merck & Company, Inc. (NYSE:MRK) – Equities research analysts at SunTrust Banks raised their FY2017 earnings per share estimates for Merck & in a report issued on Monday. SunTrust Banks analyst J. Boris now expects that the company will post earnings per share of $3.94 for the year, up from their previous estimate of $3.88. SunTrust Banks currently has a “Hold” rating on the stock. SunTrust Banks also issued estimates for Merck &’s FY2018 earnings at $4.07 EPS and FY2020 earnings at $4.47 EPS.
A number of other equities analysts have also recently issued reports on MRK. UBS AG dropped their price target on shares of Merck & from $72.00 to $67.00 and set a “buy” rating on the stock in a research note on Monday. J P Morgan Chase & Co set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a research note on Sunday. Barclays PLC cut shares of Merck & from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $72.00 to $62.00 in a research note on Monday. BMO Capital Markets set a $68.00 price target on shares of Merck & and gave the stock a “buy” rating in a research note on Monday. Finally, HSBC Holdings plc upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. Merck & currently has a consensus rating of “Hold” and an average target price of $67.53.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/10/31/merck-company-inc-mrk-to-post-fy2017-earnings-of-3-94-per-share-suntrust-banks-forecasts.html.
Merck & (NYSE MRK) opened at 54.71 on Tuesday. The firm has a 50 day moving average of $63.99 and a 200-day moving average of $63.61. The company has a market capitalization of $149.21 billion, a price-to-earnings ratio of 29.62 and a beta of 0.80. Merck & has a 1-year low of $54.41 and a 1-year high of $66.80.
Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The firm had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same period last year, the firm earned $1.07 earnings per share. The business’s quarterly revenue was down 2.0% compared to the same quarter last year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Fort Washington Investment Advisors Inc. OH grew its holdings in Merck & by 133.4% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock valued at $9,165,000 after buying an additional 82,454 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Merck & by 2.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock valued at $269,678,000 after buying an additional 107,201 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in Merck & by 41.9% during the 2nd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock valued at $19,028,000 after buying an additional 87,443 shares in the last quarter. Stevens Capital Management LP purchased a new stake in Merck & during the 1st quarter valued at approximately $15,126,000. Finally, Trust Co grew its holdings in Merck & by 2.8% during the 1st quarter. Trust Co now owns 68,789 shares of the company’s stock valued at $4,371,000 after buying an additional 1,852 shares in the last quarter. 72.86% of the stock is owned by institutional investors and hedge funds.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.